Comparison of the prognostic utility of the revised International Prognostic Scoring System and the French Prognostic Scoring System in azacitidine-treated patients with myelodysplastic syndromes

Prolonged Administration of Azacitidine With or Without Entinostat for Myelodysplastic Syndrome and Acute Myeloid Leukemia With Myelodysplasia-Related Changes: Results of the US Leukemia Intergroup Trial E1905

(2014) Thomas Prebet et al.   JOURNAL OF CLINICAL ONCOLOGY

Validation of the revised International Prognostic Scoring System in treated patients with myelodysplastic syndromes

(2013) Asmita Mishra et al.   AMERICAN JOURNAL OF HEMATOLOGY

Current therapy of myelodysplastic syndromes

(2013) Amer M. Zeidan et al.   BLOOD REVIEWS

Revised International Prognostic Scoring System (IPSS) Predicts Survival and Leukemic Evolution of Myelodysplastic Syndromes Significantly Better Than IPSS and WHO Prognostic Scoring System: Validation by the Gruppo Romano Mielodisplasie Italian Regional Database

(2013) Maria Teresa Voso et al.   JOURNAL OF CLINICAL ONCOLOGY

Impact of the revised International Prognostic Scoring System on the outcome of patients with acute myeloid leukemia with or without antecedent myelodysplastic syndrome

(2013) F Stölzel et al.   LEUKEMIA

Validation of the revised International Prognostic Scoring System (IPSS-R) in patients with myelodysplastic syndrome: A multicenter study

(2013) Judith Neukirchen et al.   LEUKEMIA RESEARCH

There’s Risk, and Then There’s RISK: The Latest Clinical Prognostic Risk Stratification Models in Myelodysplastic Syndromes

(2013) Amer M. Zeidan et al.   Current Hematologic Malignancy Reports

Can hypomethylating agents provide a platform for curative therapy in myelodysplastic syndromes?

(2012) David P. Steensma   BEST PRACTICE & RESEARCH CLINICAL HAEMATOLOGY

Long-term outcome of higher-risk MDS patients treated with azacitidine: an update of the GFM compassionate program cohort

(2012) R. Itzykson et al.   BLOOD

The revised IPSS is a powerful tool to evaluate the outcome of MDS patients treated with azacitidine: the GFM experience

(2012) M. Lamarque et al.   BLOOD

Revised International Prognostic Scoring System for Myelodysplastic Syndromes

(2012) P. L. Greenberg et al.   BLOOD

Application of French prognostic score to patients with International Prognostic Scoring System intermediate-2 or high risk myelodysplastic syndromes treated with 5-azacitidine is able to predict overall survival and rate of response

(2012) Massimo Breccia et al.   LEUKEMIA & LYMPHOMA

Platelet doubling after the first azacitidine cycle is a promising predictor for response in myelodysplastic syndromes (MDS), chronic myelomonocytic leukaemia (CMML) and acute myeloid leukaemia (AML) patients in the Dutch azacitidine compassionate named p

(2011) Lieke H. van der Helm et al.   BRITISH JOURNAL OF HAEMATOLOGY

Outcome of High-Risk Myelodysplastic Syndrome After Azacitidine Treatment Failure

(2011) Thomas Prébet et al.   JOURNAL OF CLINICAL ONCOLOGY

Impact of TET2 mutations on response rate to azacitidine in myelodysplastic syndromes and low blast count acute myeloid leukemias

(2011) R Itzykson et al.   LEUKEMIA

Prognostic factors for response and overall survival in 282 patients with higher-risk myelodysplastic syndromes treated with azacitidine

(2010) R. Itzykson et al.   BLOOD

Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study

(2009) Pierre Fenaux et al.   LANCET ONCOLOGY